The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020

Pizzato, Margherita; Li, Mengmeng; Vignat, Jérôme; Laversanne, Mathieu; Singh, Deependra; Vecchia, Carlo La; Vaccarella, Salvatore

doi:10.1016/s2213-8587(22)00035-3

Cited by 339 publications

(222 citation statements)

References 59 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…Differentiated thyroid cancer (DTC) represents the most common endocrine tumor, showing an increasing incidence trend during the last decades [ 1 ]. Papillary thyroid carcinoma (PTC) is the most common histological subtype [ 2 ] and a large number of new cases are related to small and indolent PTC, often found incidentally due to the increased use of diagnostic investigations [ 3 , 4 ]. Despite the steep increase in DTC incidence, the specific five-year-survival rates are about 98% [ 1 ] and the related age-adjusted mortality remains stable (about 0.5 per 100,000 per year), with no further expected change according to recent global estimates [ 4 ].…”

Section: Differentiated Thyroid Cancer: Mortality and Recurrence Risksmentioning

confidence: 99%

“…Papillary thyroid carcinoma (PTC) is the most common histological subtype [ 2 ] and a large number of new cases are related to small and indolent PTC, often found incidentally due to the increased use of diagnostic investigations [ 3 , 4 ]. Despite the steep increase in DTC incidence, the specific five-year-survival rates are about 98% [ 1 ] and the related age-adjusted mortality remains stable (about 0.5 per 100,000 per year), with no further expected change according to recent global estimates [ 4 ]. The extremely good prognosis of DTC and an increased awareness of the risks of treatments possibly resulting in life-long quality of life (QoL) impairment, has promoted a wide revision of diagnostic and management strategies [ 2 ].…”

Section: Differentiated Thyroid Cancer: Mortality and Recurrence Risksmentioning

confidence: 99%

See 1 more Smart Citation

Strategies for Radioiodine Treatment: What’s New

Sparano

Moog

Hadoux

et al. 2022

Cancers

View full text Add to dashboard Cite

Radioiodine treatment (RAI) represents the most widespread and effective therapy for differentiated thyroid cancer (DTC). RAI goals encompass ablative (destruction of thyroid remnants, to enhance thyroglobulin predictive value), adjuvant (destruction of microscopic disease to reduce recurrences), and therapeutic (in case of macroscopic iodine avid lesions) purposes, but its use has evolved over time. Randomized trial results have enabled the refinement of RAI indications, moving from a standardized practice to a tailored approach. In most cases, low-risk patients may safely avoid RAI, but where necessary, a simplified protocol, based on lower iodine activities and human recombinant TSH preparation, proved to be just as effective, reducing overtreatment or useless impairment of quality of life. In pediatric DTC, RAI treatments may allow tumor healing even at the advanced stages. Finally, new challenges have arisen with the advancement in redifferentiation protocols, through which RAI still represents a leading therapy, even in former iodine refractory cases. RAI therapy is usually well-tolerated at low activities rates, but some concerns exist concerning higher cumulative doses and long-term outcomes. Despite these achievements, several issues still need to be addressed in terms of RAI indications and protocols, heading toward the RAI strategy of the future.

show abstract

Section: Differentiated Thyroid Cancer: Mortality and Recurrence Risksmentioning

confidence: 99%

Section: Differentiated Thyroid Cancer: Mortality and Recurrence Risksmentioning

confidence: 99%

Strategies for Radioiodine Treatment: What’s New

Sparano

Moog

Hadoux

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Epidemiological studies have shown a worldwide increase in thyroid cancer incidence in recent decades (1,2). To a large extent, the increase is due to a more frequent detection of papillary thyroid carcinoma as compared to other thyroid cancer histotypes, and particularly of low-grade tumors (3)(4)(5)(6)(7)(8) which intrinsically include papillary thyroid microcarcinomas (MPTCs) measuring up to 10 mm.…”

Section: Introductionmentioning

confidence: 99%

The high degree of similarity in histopathological and clinical characteristics between radiogenic and sporadic papillary thyroid microcarcinomas in young patients

et al. 2022

View full text Add to dashboard Cite

The potential overtreatment of patients with papillary thyroid microcarcinoma (MPTC) has been an important clinical problem in endocrine oncology over the past decade. At the same time, current clinical guidelines tend to consider prior radiation exposure as a contraindication to less extensive surgery, even for low-risk thyroid carcinomas, which primarily include microcarcinomas. This study aims to determine whether there are differences in the behavior of MPTC of two etiological forms (radiogenic and sporadic), including invasive properties, clinical data, and recurrence in patients aged up to 30 years. For this purpose, 136 radiogenic (from patients aged up to 18 years at the time of the Chornobyl accident) and 83 sporadic (from patients born after the Chornobyl accident) MPTCs were selected and compared using univariate and multivariate statistical methods in a whole group and in age and tumor size subgroups. No evidence of more aggressive clinical and histopathological behavior of radiogenic MPTCs as compared to sporadic tumors for basic structural, invasive characteristics, treatment options, and postoperative follow-up results was found. Moreover, radiogenic MPTCs were characterized by the lower frequencies of oncocytic changes (OR = 0.392, p = 0.004), nodal disease (OR = 0.509, p = 0.050), and more frequent complete remission (excellent response) after radioiodine therapy (OR = 9.174, p = 0.008). These results strongly suggest that internal irradiation does not affect tumor phenotype, does not associate with more pronounced invasive properties, and does not worsen prognosis in pediatric or young adult patients with MPTC, implying that radiation history may be not a pivotal factor for determining treatment strategy in such patients.

show abstract

“…Thyroid cancer (TC) has become one of the most common malignancies of the endocrine system over the past few decades, with a steady increase in global morbidity and mortality and a strong female predominance, which is well validated by the finding that the incidence in women in most populations is approximately three times that in men ( 42 ). Since 2003, the incidence of thyroid cancer in China has suddenly started to rise rapidly and has maintained an annual percentage change of approximately 14.51 from 2003 to 2007, while urban women have witnessed a faster rate of change, and by 2012, thyroid cancer had become one of the ten most common cancers ( 43 – 45 ).…”

Section: Role and Mechanism Of Tmem88 In Malignant Tumorsmentioning

confidence: 96%

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Cai

Ni²,

Wang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

According to authoritative surveys, the overall morbidity and mortality of malignant tumors show an upward trend, and it is predicted that this trend will not be well contained in the upcoming new period. Since the influencing factors, pathogenesis, and progression characteristics of malignant tumors have not been fully elucidated, the existing treatment strategies, mainly including surgical resection, ablation therapy and chemotherapy, cannot achieve satisfactory results. Therefore, exploring potential therapeutic targets and clarifying their functions and mechanisms in continuous research and practice will provide new ideas and possibilities for the treatment of malignant tumors. Recently, a double-transmembrane protein named transmembrane protein 88 (TMEM88) was reported to regulate changes in downstream effectors by mediating different signaling pathways and was confirmed to be widely involved in cell proliferation, differentiation, apoptosis and tumor progression. At present, abnormal changes in TMEM88 have been found in breast cancer, ovarian cancer, lung cancer, thyroid cancer and other malignant tumors, which has also attracted the attention of tumor research and attempted to clarify its function and mechanism. However, due to the lack of systematic generalization, comprehensive and detailed research results have not been comprehensively summarized. In view of this, this article will describe in detail the changes in TMEM88 in the occurrence and development of malignant tumors, comprehensively summarize the corresponding molecular mechanisms, and explore the potential of targeting TMEM88 in the treatment of malignant tumors to provide valuable candidate targets and promising intervention strategies for the diagnosis and cure of malignant tumors.

show abstract

The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020

Cited by 339 publications

References 59 publications

Strategies for Radioiodine Treatment: What’s New

Strategies for Radioiodine Treatment: What’s New

The high degree of similarity in histopathological and clinical characteristics between radiogenic and sporadic papillary thyroid microcarcinomas in young patients

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors

Contact Info

Product

Resources

About